Gambaran Umum
FibroBiologics, Inc., based in the United States, operates primarily within the biotechnology sector, focusing on harnessing the therapeutic potential of fibroblasts. Fibroblasts are cells essential for tissue repair and regeneration, making them pivotal in treatment innovations for various diseases. FibroBiologics is actively engaged in developing a diverse pipeline of fibroblast-based therapies, which include projects targeting conditions such as chronic kidney disease, liver cirrhosis, and multiple sclerosis. These initiatives represent the company's commitment to advancing regenerative medicine by exploiting the inherent healing capabilities of fibroblasts, aiming to provide novel treatments that can offer significant improvements over existing therapies in terms of efficacy and safety.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk FibroBiologics, Inc. per 2025 Jun 30 adalah -16.08 MM.
- Nilai net income untuk FibroBiologics, Inc. per 2025 Jun 30 adalah -13.22 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | -16.08 | -13.22 | |
| 2025-03-31 | -14.82 | -7.67 | |
| 2024-12-31 | -13.74 | -11.16 | |
| 2024-09-30 | -12.51 | -17.78 | |
| 2024-06-30 | -11.21 | -19.47 | |
| 2024-03-31 | -10.07 | -22.53 | |
| 2023-12-31 | -8.89 | -16.48 | |
| 2023-09-30 | -7.71 | -8.29 | |
| 2023-06-30 | -7.00 | -7.66 | |
| 2023-03-31 | -5.82 | -6.52 | |
| 2022-12-31 | -4.47 | -5.12 | |
| 2021-12-31 | -1.58 | -1.58 | |
| 2020-12-31 | -1.17 | -1.17 |
Laporan Laba Rugi: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | -0.57 | -0.57 |
| 2024-06-30 | -0.65 | -0.65 |
| 2024-03-31 | -0.78 | -0.78 |
| 2023-12-31 | -0.68 | |
| 2023-09-30 | -0.38 | -0.38 |
| 2023-06-30 | -0.36 | -0.36 |
| 2023-03-31 | -0.32 | -0.32 |
| 2022-12-31 | -0.18 | |
| 2021-12-31 | -0.18 | -0.18 |
| 2020-12-31 | -0.13 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk FibroBiologics, Inc. per 2025 Jun 30 adalah -14.94 MM.
- Nilai cash from investing activities untuk FibroBiologics, Inc. per 2025 Jun 30 adalah -0.37 MM.
- Nilai kas dari aktivitas pendanaan untuk FibroBiologics, Inc. per 2025 Jun 30 adalah 18.18 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -14.94 | -0.37 | 18.18 |
| 2025-03-31 | -12.90 | -0.22 | 13.63 |
| 2024-12-31 | -11.90 | -0.18 | 16.91 |
| 2024-09-30 | -10.43 | -0.09 | 7.58 |
| 2024-06-30 | -8.96 | -0.49 | 4.05 |
| 2024-03-31 | -8.64 | -0.45 | 2.50 |
| 2023-12-31 | -6.40 | -0.49 | 13.79 |
| 2023-09-30 | -5.97 | -0.49 | 15.94 |
| 2023-06-30 | -6.20 | -0.08 | 14.70 |
| 2023-03-31 | -5.34 | -0.06 | 18.45 |
| 2022-12-31 | -4.07 | 5.92 | |
| 2021-12-31 | -1.41 | 1.82 | |
| 2020-12-31 | -1.17 | 1.17 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2021-12-31 | |||
| 2020-12-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 |
Efektivitas Manajemen
- roa untuk FibroBiologics, Inc. pada 2025 Jun 30 adalah -0.86.
- roic untuk FibroBiologics, Inc. pada 2025 Jun 30 adalah -0.81.
- croic untuk FibroBiologics, Inc. pada 2025 Jun 30 adalah 0.05.
- ocroic untuk FibroBiologics, Inc. pada 2025 Jun 30 adalah -1.36.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2025-06-30 | -0.86 | -0.81 | 0.05 | -1.36 | |
| 2025-03-31 | -1.56 | -4.14 | -0.68 | -2.43 | |
| 2024-12-31 | -1.50 | -8.91 | -4.14 | -0.68 | -2.43 |
| 2024-09-30 | -1.46 | -1.69 | |||
| 2024-06-30 | -4.67 | ||||
| 2024-03-31 | -3.42 | -5.25 | 2.20 | -2.04 | |
| 2023-12-31 | -0.66 | 0.76 | -0.48 | ||
| 2023-09-30 | -0.58 | 0.64 | -0.47 | ||
| 2023-06-30 | -16.37 | -0.41 | 0.45 | -0.33 | |
| 2023-03-31 | -13.93 | -0.35 | 0.27 | -0.29 | |
| 2022-12-31 | |||||
| 2021-12-31 | -6.73 | 1.73 | -6.00 | ||
| 2020-12-31 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2021-12-31 | |||
| 2020-12-31 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) | 1958777 |
Grupong Pang-industriya
| SIC 2834 - Pharmaceutical Preparations |
